Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;34 Suppl 1(Suppl1):26-28.
doi: 10.37201/req/s01.07.2021. Epub 2021 Sep 30.

Dalbavancin

J Barberán  1 , A de la Cuerda, L C Barberán
Affiliations
Review

Dalbavancin

J Barberán et al. Rev Esp Quimioter. 2021 Sep.

Abstract

Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacterial skin and skin structure infections (ABSSSIs), but in real-life clinical practice it has already been used successfully and safely in other infections, especially as consolidation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Structure of dalbavancin
See this image and copyright information in PMC

References

    1. European Committee on Antimicrobial Susceptibility Testing (EU-CAST). Break- point tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http://www.eucast.org [accessed 28 July 2021].
    1. Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16. J Antimicrob Chemother 2018; 73:2748–2756. doi:10.1093/jac/dky235. - DOI - PubMed
    1. Azanza JR, Sádaba B, Reis J. Dalbavancina: parámetros farmacocinéticos y farmacodinámicos. Enferm Infecc Microbiol Clin. 2017; 35(Supl 1):22-7. doi: 10.1016/S0213-005X(17)30031-9 - DOI - PubMed
    1. Durante-Mangoni E, Gambardella M, Lula VD, De Stefano GF, Corrado MF, Esposito Vet al. . Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents 2020; 56:106107. doi: 10.1016/j.ijantimicag.2020.106107. - DOI - PubMed
    1. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna Het al. . Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens. Clin Infect Dis 2005; 40:374–80. doi: 10.1086/427283. - DOI - PubMed

MeSH terms